Provided by Tiger Fintech (Singapore) Pte. Ltd.

Unicycive Therapeutics, Inc.

0.6250
+0.01492.44%
Volume:309.03K
Turnover:192.88K
Market Cap:74.82M
PE:-1.11
High:0.6387
Open:0.6045
Low:0.6045
Close:0.6101
Loading ...

Positive Buy Recommendation for Unicycive Therapeutics Driven by Promising Trial Results and Revenue Forecasts

TIPRANKS
·
08 Jan

Unicycive Therapeutics announces publication of OLC dose escalation data

TIPRANKS
·
07 Jan

Unicycive Therapeutics Announces Publication of Positive Oxylanthanum Carbonate (OLC) Dose Escalation Data in Clinical and Translational Science

GlobeNewswire
·
07 Jan

Unicycive announces puvlication of OLC positive bioequivalence data

TIPRANKS
·
17 Dec 2024

Unicycive Therapeutics Announces Publication of Oxylanthanum Carbonate (OLC) Positive Bioequivalence Data in Clinical Therapeutics

GlobeNewswire
·
17 Dec 2024

Breakeven On The Horizon For Unicycive Therapeutics, Inc. (NASDAQ:UNCY)

Simply Wall St.
·
28 Nov 2024

Unicycive Therapeutics Price Target Maintained With a $3.00/Share by Benchmark

Dow Jones
·
22 Nov 2024

Unicycive Therapeutics to Participate in Two Upcoming Investor Conferences Including a Fireside Chat at the Piper Sandler 36th Annual Healthcare Conference

GlobeNewswire
·
21 Nov 2024

Strategic Market Position and FDA Milestone Propel Unicycive Therapeutics to ‘Buy’ Rating

TIPRANKS
·
15 Nov 2024

BRIEF-Unicycive Announces Q3 2024 Financial Results And Provides Business Update

Reuters
·
13 Nov 2024

Unicycive Therapeutics reports Q3 EPS (13c), consensus (15c)

TIPRANKS
·
13 Nov 2024

Unicycive Therapeutics Q3 Income From Operations USD -6.251 Million

THOMSON REUTERS
·
13 Nov 2024

Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update

THOMSON REUTERS
·
13 Nov 2024

Unicycive Therapeutics Inc Q3 Shr View $-0.15 -- Lseg Ibes Data

THOMSON REUTERS
·
13 Nov 2024

Press Release: Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update

Dow Jones
·
13 Nov 2024

Unicycive Therapeutics Says FDA Accepts New Drug Application for Oxylanthanum Carbonate

MT Newswires Live
·
11 Nov 2024

Unicycive: FDA to Review Lead Drug Candidate for Hyperphosphatemia

Dow Jones
·
11 Nov 2024

Unicycive Therapeutics announces U.S. FDA acceptane for NDA for OLC

TIPRANKS
·
11 Nov 2024

Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (Nda) for Oxylanthanum Carbonate (Olc) for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease on Dialysis

THOMSON REUTERS
·
11 Nov 2024

Unicycive Therapeutics Inc - Preparing for 2025 Commercial Launch of Olc

THOMSON REUTERS
·
11 Nov 2024